The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.
 
Tomás Pascual
No Relationships to Disclose
 
Laia Pare
No Relationships to Disclose
 
Patricia Galvan
No Relationships to Disclose
 
Miguel A. Izquierdo
Employment - Novartis
 
Vanessa Rodrik-Outmezguine
Employment - Novartis
 
Barbara Adamo
No Relationships to Disclose
 
Maria Vidal
No Relationships to Disclose
 
Jamunarani Veeraraghavan
No Relationships to Disclose
 
Rachel Schiff
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Lilly
 
C. Kent Osborne
Stock and Other Ownership Interests - Genetex
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Ventana Medical Systems
Patents, Royalties, Other Intellectual Property - Royalties for co editor of Diseases of the Breast
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Ventana Medical Systems
 
Mothaffar F. Rimawi
Consulting or Advisory Role - Celgene
 
Paolo Nuciforo
No Relationships to Disclose
 
Aleix Prat
Consulting or Advisory Role - NanoString Technologies (Inst)
Research Funding - NanoString Technologies (Inst)